Research on Reimbursement Management of Innovative Drugs Abroad and Its Enlightenment to China  

作　　者：Yu Hanshuang Huang Xianqin Wang Huiyan Sun Lihua 

机构地区：[1]School of Business Administration,Shenyang Pharmaceutical University,Shenyang 110016,China [2]School of Pharmacy,Peking University,Beijing 100191,China

出　　处：《Asian Journal of Social Pharmacy》2024年第1期1-8,共8页亚洲社会药学（英文）

摘　　要：Objective To analyze the reimbursement policies of innovative drugs in some developed countries,and to provide reference for future reimbursement management in China.Methods Literature research method was used to study the policies related to the reimbursement management of innovative drugs in Germany,France and Japan,and their successful experience was summarized.Results and Conclusion China should establish an open and transparent value evaluation standard to improve the medical insurance reimbursement management of innovative drugs.Besides,the value of innovative drugs should be taken as an important basis for reimbursement decisions,and an independent third-party value evaluation agency must be established.

关 键 词：innovative drug medical insurance REIMBURSEMENT 

分 类 号：R197.323[医药卫生—卫生事业管理]